Dr Reddy’s Laboratories on Friday announced the launch of Doxycycline capsules 40 mg, in the US market.
The drug is a therapeutic generic equivalent of ORACEA (doxycycline, USP) capsules (40 mg), approved by the US Food and Drug Administration (USFDA), the company said in a statement.
“This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. Do not use doxycycline capsules for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease,” the firm further stated.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.